FDA grants priority review for Daiichi Sankyo-Merck’s lung cancer therapy

[cafead]

via The US Food and Drug Administration (FDA) has granted priority review to Daiichi Sankyo and Merck’s biologics license application (BLA) for patritumab deruxtecan, to potentially treat non-small cell lung cancer (NSCLC) in adults.

article source